Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

28 March 2019. Related: Conference reports, CROI 26 (Retrovirus) 2019, Conference index.

Introduction

This year the Conference on Retroviruses and Opportunistic Infections (CROI 2019) was held in Seattle from 4–7 March.

The meeting had an exciting programme with research that we will report over at least the next three issues of HTB.

CROI is notable for providing same-day or next-day webcasts for most talks and comprehensive online access to abstracts and PDF files for posters.

http://www.croiconference.org

BHIVA have also organised an excellent series of CROI feedback workshops and slides and webcasts from the London meeting are also posted online.

https://www.bhiva.org/BestofCROI2019

This is the second set of HTB reports from the CROI.

• Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

• Capsid inhibitor GS-6297 shows potential for 3-monthly injections

• First phase 1 results from bNAb PGT121 in HIV positive people

• Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI Studies

• Same-day ART is effective in San Francisco Rapid-ART clinic

• Integrase inhibitors and neural tube defects: more data still needed

• Double-dose levonorgestrel implant does not overcome interaction with efavirenz

• Efavirenz and rifampicin together reduce levels of injectable contraception

• Bedaquiline and delamanid safe when given together to treat drug resistant TB

• Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes